New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
07:22 EDTHTWRHeartWare recent pullback a buying opportunity, says JPMorgan
JPMorgan recommends using the recent pullback in shares of HeartWare as a buying opportunity. The firm believes concerns over the company's VAD market share are misplaced and reiterates an Overweight rating on the name with a $128 price target.
News For HTWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 31, 2014
07:51 EDTHTWRHeartWare price target lowered to $115 from $125 at Canaccord
Subscribe for More Information
October 30, 2014
07:00 EDTHTWRHeartWare reports Q3 EPS (64c), consensus (65c)
Subscribe for More Information
October 21, 2014
15:00 EDTHTWRUpdate suggests HeartWare CE mark trial on track, says Wells Fargo
Wells Fargo said the clinicaltrials.gov posting for HeartWare's MVAD CE Mark trial, which had not been changed since April 2013, was updated on October 16 and now indicates the trial is scheduled to start in April 2015. Wells expects HeartWare to update on MVAD on its Q3 call next week, but the firm said that it does not expect any major surprises based on the updated posting. Wells Fargo maintains its Market Perform rating on HeartWare.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use